Advances in biological therapies for dyslipidemias and atherosclerosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in biological therapies for dyslipidemias and atherosclerosis
Authors
Keywords
Monoclonal antibodies (mAbs), Vaccines, Immunotherapy, Antisense oligonucleotides (ASOs), Genome/base editing, Gene therapy, Precision medicine
Journal
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 116, Issue -, Pages 154461
Publisher
Elsevier BV
Online
2020-12-05
DOI
10.1016/j.metabol.2020.154461
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
- (2020) Raul D. Santos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The promise and challenge of therapeutic genome editing
- (2020) Jennifer A. Doudna NATURE
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- (2020) Sotirios Tsimikas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo
- (2020) Liu Yang et al. Molecular Therapy-Nucleic Acids
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
- (2020) Matthew J Budoff et al. EUROPEAN HEART JOURNAL
- Evinacumab for Homozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bioconjugated oligonucleotides: recent developments and therapeutic applications
- (2019) sebastien benizri et al. BIOCONJUGATE CHEMISTRY
- In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
- (2019) Alba Carreras et al. BMC BIOLOGY
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Application of PCSK9 Inhibitors in Practice
- (2019) Tina M. Kaufman et al. CIRCULATION RESEARCH
- Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
- (2019) Michael B. Boffa et al. Nature Reviews Cardiology
- Adeno-associated virus vector as a platform for gene therapy delivery
- (2019) Dan Wang et al. NATURE REVIEWS DRUG DISCOVERY
- Anticytokine Agents
- (2019) Paul M Ridker CIRCULATION RESEARCH
- Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art
- (2019) Fatemeh Vahdat Lasemi et al. DRUG DISCOVERY TODAY
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
- (2019) Veronica J Alexander et al. EUROPEAN HEART JOURNAL
- The next generation of CRISPR–Cas technologies and applications
- (2019) Adrian Pickar-Oliver et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Triple-Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases
- (2019) Lingmin Zhang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Volanesorsen: First Global Approval
- (2019) Julia Paik et al. DRUGS
- The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease
- (2019) Eftaxia-Konstantina Valanti et al. CURRENT OPINION IN LIPIDOLOGY
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- (2019) Joseph L. Witztum et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia
- (2019) Huan Zhao et al. CIRCULATION
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
- (2019) Erin D. Michos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduction of myocardial ischaemia–reperfusion injury by inactivating oxidized phospholipids
- (2018) Calvin Yeang et al. CARDIOVASCULAR RESEARCH
- Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
- (2018) Alexandra C. Chadwick et al. CIRCULATION
- Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
- (2018) Emelia J. Benjamin et al. CIRCULATION
- Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
- (2018) Eswar Kandaswamy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway
- (2018) Dimitris Theofilatos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dyslipidaemia: In vivo genome editing of ANGPTL3: a therapy for atherosclerosis?
- (2018) June-Wha Rhee et al. Nature Reviews Cardiology
- Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – Novel insights and future directions in diagnosis and therapy ,
- (2018) Adam Hartley et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
- (2018) Xuchu Que et al. NATURE
- CRISPR-Cas guides the future of genetic engineering
- (2018) Gavin J. Knott et al. SCIENCE
- IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3)
- (2018) Victor J. van den Berg et al. EBioMedicine
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
- (2018) Laurens F. Reeskamp et al. ATHEROSCLEROSIS
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Base editing: precision chemistry on the genome and transcriptome of living cells
- (2018) Holly A. Rees et al. NATURE REVIEWS GENETICS
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
- (2017) Wolfgang Poller et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability
- (2017) Daniel B. Mark et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
- (2017) Carl E. Orringer et al. Journal of Clinical Lipidology
- A Test in Context: Lipoprotein(a)
- (2017) Sotirios Tsimikas JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
- (2017) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- After Glybera's withdrawal, what's next for gene therapy?
- (2017) Melanie Senior NATURE BIOTECHNOLOGY
- A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels
- (2017) Sumeet A Khetarpal et al. NATURE MEDICINE
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
- (2017) Mark J. Graham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Antisense Oligonucleotides
- (2017) Stanley T. Crooke Nucleic Acid Therapeutics
- Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation
- (2017) Beatrice Oehler et al. Scientific Reports
- Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia
- (2017) Jenny A. Greig et al. Human Gene Therapy Clinical Development
- Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR+/− Rhesus Macaques
- (2017) Jenny A. Greig et al. Human Gene Therapy Clinical Development
- Familial hypercholesterolaemia
- (2017) Joep C. Defesche et al. Nature Reviews Disease Primers
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
- (2017) Ann Marie Navar et al. JAMA Cardiology
- Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits
- (2017) Bradley K. Wacker et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease
- (2017) Kelsey E. Jarrett et al. Scientific Reports
- Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE)
- (2016) Shu Ren et al. AMERICAN HEART JOURNAL
- Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of AtherosclerosisHighlights
- (2016) Bradley K. Wacker et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary EventsSignificance
- (2016) Harry Björkbacka et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis
- (2016) Shin-ya Morita BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
- (2016) Ola Kleveland et al. EUROPEAN HEART JOURNAL
- Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
- (2016) Alan Chait et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
- (2016) Nicholas J Viney et al. LANCET
- Genome editing in cardiovascular diseases
- (2016) Alanna Strong et al. Nature Reviews Cardiology
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
- (2016) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients
- (2016) Tong Shen et al. PHARMACEUTICAL RESEARCH
- Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes
- (2016) Giuseppe Asciutto et al. STROKE
- Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
- (2016) Rosie Z Yu et al. Molecular Therapy-Nucleic Acids
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis
- (2015) Luke J Leman Clinical Lipidology
- Acute myocardial infarction and influenza: a meta-analysis of case–control studies
- (2015) Michelle Barnes et al. HEART
- ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
- (2015) Viktoria Gusarova et al. JOURNAL OF LIPID RESEARCH
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- In vivo genome editing using Staphylococcus aureus Cas9
- (2015) F. Ann Ran et al. NATURE
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein C-III: From Pathophysiology to Pharmacology
- (2015) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
- (2015) Joshua Lehrer-Graiwer et al. JACC-Cardiovascular Imaging
- HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
- (2015) Kuang-Yuh Chyu et al. Frontiers in Pharmacology
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
- (2014) Amit C. Nathwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice
- (2014) Thazha P. Prakash et al. NUCLEIC ACIDS RESEARCH
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia
- (2012) Sadik H. Kassim et al. HUMAN GENE THERAPY
- Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions
- (2012) Rogier A. van Dijk et al. JOURNAL OF LIPID RESEARCH
- Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
- (2012) Tsuyoshi Yamamoto et al. Molecular Therapy-Nucleic Acids
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
- (2011) Esther Merki et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Expression of Apolipoprotein A-I in Rabbit Carotid Endothelium Protects Against Atherosclerosis
- (2011) Rowan Flynn et al. MOLECULAR THERAPY
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
- (2011) Amit C. Nathwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study
- (2010) Aldar S Bourinbaiar et al. Lipids in Health and Disease
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Gene Therapy in a Humanized Mouse Model of Familial Hypercholesterolemia Leads to Marked Regression of Atherosclerosis
- (2010) Sadik H. Kassim et al. PLoS One
- Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study
- (2008) A. Ciszewski et al. EUROPEAN HEART JOURNAL
- High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction
- (2008) P. Sjogren et al. EUROPEAN HEART JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search